MYH11 and acute myeloid leukemia: Over the last two decades, efforts have been made to improve the assessment of disease response and, especially, the monitoring over time, because although being classified as a favorable risk category, CBFB-MYH11 AML will experience relapse in nearly 30% of patients, with an estimated RFS rate of 42%, following standard care.